G. Brusselle (Ghent, Belgium)
to present important clinical trials in respiratory medicine; to summarise key findings and discuss with the audience experts conclusions, to bring clinical trial’s abstracts into the clinical context. This session is led by a chair and two expert discussants who will facilitate the discussions and summarise key messages.
Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies D. Singh (Manchester, United Kingdom), J. Virchow (Rostock, Germany), W. Canonica (Milan, Italy), S. Corre (Parma, Italy), F. Zuccaro (Parma, Italy), M. Kots (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), S. Petruzzelli (Parma, Italy)
|     |
Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings P. D'Andrea (NJ, United States of America), O. Kornmann (Frankfurt, Germany), J. Mucsi (Gödöllo, Hungary), M. Kato (Kishiwada, Japan), L. Bandelli (NJ, United States of America), B. Sen (Hyderabad, India)
|     |
Late Breaking Abstract - Comparison of mesh and jet nebulizers with different interfaces in acute moderate to severe paediatric asthma G. Moody (Dallas, United States of America)
|     |
Ten-year follow-up of subjects who received bronchial thermoplasty (BT) in 3 randomized controlled studies (BT10+) R. Chaudhuri (Glasgow, United Kingdom), A. Rubin (Porto Alegre, Brazil), J. Fiterman (Porto Alegre, Brazil), K. Sumino (St. Louis, MO, United States of America), J. Lapa E Silva (Rio de Janiero, Brazil), R. Niven (Manchester, United Kingdom), S. Siddiqui (Leicester, United Kingdom), R. Olivenstein (Montreal, QC, Canada), K. Klooster (Groningen, Netherlands), C. Mcevoy (St. Paul, MN, United States of America), P. Shah (London, United Kingdom), M. Simoff (Detroit, MI, United States of America), D. Duhamel (Arlington, VA, United States of America), S. Khatri (Cleveland, OH, United States of America), R. Barbers (Los Angeles, CA, United States of America), F. Nolan (Marlborough, MA, United States of America), M. Laviolette (Quebec, QC, Canada)
|    |
Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials J. Mullol (Barcelona, Spain), T. Laidlaw (Boston, United States of America), N. Amin (Tarrytown, United States of America), C. Bachert (Ghent (Belgium) and Stockholm, Sweden), J. Han (Norfolk, United States of America), P. Hellings (Leuven, Belgium), G. Canonica (Milan, Italy), S. Cho (Tampa, United States of America), J. Maspero (Buenos Aires, Argentina), M. Desrosiers (Montreal, Canada), C. Hopkins (London, United Kingdom), P. Paggiaro (Pisa, Italy), M. Zhang (Bridgewater, United States of America), X. Lu (Bridgewater, United States of America), N. Patel (Bridgewater, United States of America), N. Graham (Tarrytown, United States of America), H. Staudinger (Bridgewater, United States of America), L. Mannent (Chilly-Mazarin, France)
|    |
Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma R. Shrimanker (Oxford, United Kingdom), K. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), S. Thulborn (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), L. Xue (Oxford, United Kingdom), G. Hynes (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), M. Kots (Parma, Italy), L. Girardello (Verona, Italy), S. Petruzzelli (Verona, Italy), J. Steiner (Oxford, United Kingdom), S. Vinall (Abingdon, United Kingdom), M. Hunter (Abingdon, United Kingdom), R. Pettipher (Abingdon, United Kingdom), I. Pavord (Oxford, United Kingdom)
|     |
Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma S. Sridhar (Gaithersburg, MD, United States of America), W. Zhao (Gaithersburg, MD, United States of America), T. Pham (Gaithersburg, MD, United States of America), J. Kearley (Gaithersburg, MD, United States of America), W. White (Gaithersburg, MD, United States of America), Y. Wu (Gaithersburg, MD, United States of America), J. Parnes (Thousand Oaks, CA, United States of America), L. Roskos (Gaithersburg, MD, United States of America), J. Griffiths (Gaithersburg, MD, United States of America)
|     |